Drug Type Small molecule drug |
Synonyms EG 017, EG017, GenSci-100 + [3] |
Target |
Action modulators |
Mechanism AR modulators(Androgen Receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H17F3N4O4 |
InChIKeyIZADWOHOXMTLOG-DEOSSOPVSA-N |
CAS Registry2442621-41-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Xerophthalmia | Phase 2 | China | 20 Sep 2023 | |
| Urinary Incontinence, Stress | Phase 2 | China | 06 Jan 2022 | |
| Urinary Incontinence, Stress | Phase 2 | China | 06 Jan 2022 | |
| AR Positive/ER Positive/HER2 Negative Breast Cancer | Phase 1 | China | 16 May 2023 | |
| Advanced breast cancer | Phase 1 | China | 08 Mar 2023 | |
| Androgenetic Alopecia | Preclinical | China | - |





